XL-protein Freising

Superior Biopharmaceuticals

Technology

PASylation® is a superior alternative to PEGylation which enables second generation biopharmaceuticals with extended plasma half-life and enhanced action. XL-protein’s technology allows a less frequent and lower dosing together with better tolerability, thus making treatment cheaper and supporting patient compliance and safety.

Partnering

With its strong proprietary technology position, including a broad basis of preclinical data, XL-protein focuses at the preclinical as well clinical development of PASylated proteins in several disease areas. To uncover the full potential of the PASylation technology XL-protein offers licensing opportunities on several levels.